Pfizer/Mylan Merger Creates Generic Drugs Giant
Pfizer/Mylan Merger Creates Generic Drugs Giant
GALWAY, IRELAND--August 5, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Pfizer (NYSE:PFE) (New York, New York) and Mylan (NASDAQ:MYL) (Canonsburg, Pennsylvania) are to merge their off-patent drugs businesses into a new company that will have estimated revenues of $19 billion to $20 billion to become the world's largest generic drugmaker.
Within this article: Details merger, value of new company, leading products, markets
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects